PRISM Mid-Day Movers: Biotech and Med Devices are Leading Today’s Charge.
PAVmed Inc. (NASDAQ: PAVM) is in focus after an explosive move that saw the stock spike more than 250% intraday as traders reacted to major contract news at its majority‑owned subsidiary, Lucid Diagnostics (NASDAQ: LUCD). The diversified medical‑technology company, whose portfolio includes minimally invasive and diagnostic platforms such as the EsoGuard esophageal DNA test, EsoCure esophageal ablation system, PortIO intraosseous vascular access device, and CarpX minimally invasive carpal‑tunnel system, is being rapidly re‑rated as the new Veterans Affairs contract opens EsoGuard access to more than nine million enrolled U.S. veterans for esophageal precancer testing.
Lisata Therapeutics Inc. (NASDAQ: LSTA) is soaring after the company entered into a binding term sheet to be acquired by Kuva Labs in an all‑cash deal that values the stock at 4.00 dollars per share plus two contingent value rights worth up to an additional 2.00 dollars per share. The offer represents roughly an 85% cash premium—and about a 180% total implied premium including the CVRs—over Lisata’s prior close, sending the stock up around 80–90% today as traders re‑rate the oncology‑focused biotech’s certepetide platform, which has Fast Track and multiple Orphan and Rare Pediatric Disease designations in solid tumors such as pancreatic cancer, glioma, and osteosarcoma.
Other Notable Movers:
Brand Engagement Network, Inc. (BNAI) up 33%
Aditxt Inc. (ADTX) up 17%
IO Biotech, Inc. (IOBT) down -55%
